Abstract BACKGROUND & AIMS Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of […]
Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis.
August 1, 2021
JHEP Rep